Antibody Information
General Information of This Antibody
| Antibody ID | ANI0YOJBB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h046-H4e/L7 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | G-protein coupled receptor 20 (GPR20) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
WO2018135501A1 ADC-14 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≜ 33.80% (Day 26) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day29, day 50.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST074) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≛ 18.50% (Day 26) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg, i.v.*1.
|
||||
| In Vivo Model | NCI-N87 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
WO2018135501A1 ADC-13 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≔ 38.00% (Day 45) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.3mpk.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≙ 50.00% (Day 70) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg, i.v. at day38, day 59.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST1) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≘ 56.30% (Day 89) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day55, day 75.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST020) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≕ 83.00% (Day 45) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1mpk.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≖ 90.40% (Day 45) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3mpk.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≚ 92.00% (Day 70) | Positive GPR20 expression (GPR20+++/++) | ||
| Method Description |
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day38, day 59.
|
||||
| In Vivo Model | Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST1) | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.